Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Peringkat dalam Saham #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Harga Saham
$28.53
Kapitalisasi Pasar
$1.96B
Perubahan (1 hari)
-1.65%
Perubahan (1 tahun)
109.32%
Negara
IE
Perdagangan GH Research PLC (GHRS)

Kategori

Rasio P/B untuk GH Research PLC (GHRS)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari GH Research PLC, rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk GH Research PLC dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH